Perspective Therapeutics, Inc. $CATX Shares Bought by Avidity Partners Management LPMarket Beat·Aug 1 at 02:40 AMCATX+1.83%
Perspective Therapeutics to report Q2 2026 results after market closePUBT·Jul 31 at 05:30 AMCATX+1.83%
1,055,409 Shares in Perspective Therapeutics, Inc. $CATX Bought by Yu FanMarket Beat·Jul 29 at 05:48 AMCATX+1.83%DB+1.35%
Perspective Therapeutics wins EU orphan drug status for (212Pb) VMT-α-NET in GEP-NETsPUBT·Jul 28 at 05:35 AMCATX+1.83%
791,555 Shares in Perspective Therapeutics, Inc. $CATX Bought by Octagon Capital Advisors LPMarket Beat·Jul 27 at 04:53 AMCATX+1.83%
As Q2 earnings kick off, these small-cap stocks earn an A+ for profitabilityMSN·Jul 17 at 12:21 PMCNNE-0.80%BLKB+7.00%
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Oral Presentation at the ESMO Congress 2026 | CATX Stock NewsStockTitan·Jul 17 at 03:22 AMCATX+1.83%
Perspective Therapeutics names Paul Lyne chief science officer as co-founder Schultz moves to advisor rolePUBT·Jul 8 at 05:31 AMCATX+1.83%
Perspective Therapeutics Appoints Paul Lyne, Ph.D., as Chief Science Officer; Co-Founder Michael K. Schultz, Ph.D., Transitions to Senior Scientific Advisor | CATX Stock NewsStockTitan·Jul 7 at 09:30 PMCATX+1.83%
Perspective Therapeutics Highlights Progress in Alpha Radiopharmaceutical PipelineTip Ranks·Jul 1 at 03:35 PMCATX+1.83%
Perspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed with [212Pb] VMT-α-NET in the Meningioma Cohort of a Phase 1/2a Study | CATX Stock NewsStockTitan·Jun 2 at 09:30 PMCATX+1.83%
